incid
invas
fungal
infect
rise
worldwid
due
growth
immunocompromis
popul
report
use
diagnost
assay
util
univers
extract
method
broad
spectrum
pcr
amplif
analysi
via
electrospray
ioniz
mass
spectrometri
pcresim
detect
identifi
pathogen
fungi
directli
bronchoalveolar
lavag
bal
specimen
less
hour
studi
describ
analyt
clinic
perform
assay
run
prospect
collect
clinic
bal
specimen
patient
probabl
possibl
fungal
infect
defin
eortcmsg
european
organ
research
treatment
cancermycos
studi
group
criteria
pcresim
assay
demonstr
sensit
ci
specif
ci
data
demonstr
util
noncultur
base
broad
fungal
target
molecular
diagnost
tool
rapid
accur
diagnosi
invas
fungal
infect
patient
risk
develop
fungal
diseas
diagnosi
fungal
infect
clinic
challeng
often
reli
combin
clinic
radiolog
microbiolog
factor
tradit
method
culturebas
fungal
identif
time
consum
process
fungi
requir
week
growth
identif
made
lengthi
turnaroundtim
meet
clinic
need
manag
fungal
infect
increas
frequenc
given
everenlarg
immunocompromis
patient
popul
larg
driven
widespread
use
immunesuppress
immunemodulatori
therapi
harpaz
et
al
rapid
accur
identif
fungal
pathogen
known
impact
appropri
antifung
drug
choic
sinc
fungal
pathogen
exhibit
differ
antifung
suscept
profil
albataineh
et
al
nonculturebas
technolog
develop
aid
clinic
laboratori
rapid
accur
identif
invas
fungi
technolog
includ
antibodi
detect
antigen
detect
fungal
protein
polysaccharid
proteom
profil
genom
identif
pcr
dna
sequenc
zhang
albataineh
et
al
perlin
wiederhold
technolog
vari
sensit
breadth
coverag
rapid
eas
use
technolog
pcr
provid
rapid
sensit
detect
specif
target
eg
aspergillu
speci
directli
clinic
specimen
white
et
al
remain
limit
due
inabl
detect
breadth
potenti
invas
fungi
pcresim
technolog
combin
rapid
sensit
pcr
breadth
databas
coverag
fungal
speci
pcresim
technolog
previous
evalu
detect
identif
fungi
pure
cultur
isol
retrospect
archiv
frozen
respiratori
specimen
shown
sensit
divers
speci
repres
fungi
pathogen
clade
massir
et
al
shin
et
al
unlik
previou
studi
current
studi
determin
analyt
clinic
perform
pcresim
assay
patientcons
diagnost
microbiolog
infecti
diseas
xxx
xxxx
xxx
prospect
collect
bal
sampl
analyt
perform
sensit
limit
detect
specif
pcresim
assay
fungal
detect
lack
previou
public
assess
clinic
perform
pcresim
method
appli
prospect
collect
bal
specimen
obtain
patient
suspect
high
risk
pulmonari
fungal
infect
addit
updat
detect
platform
capabl
handl
larger
input
volum
ml
vs
ml
improv
signatur
databas
rapid
process
time
hour
sampl
answer
use
result
analyz
rel
compar
standard
care
mycolog
laboratori
test
includ
cultur
biomark
histopatholog
molecular
data
along
clinic
data
patient
pcresim
assay
design
detect
identifi
pathogen
fungi
belong
genera
addit
nonpathogen
fungi
found
littl
histori
human
pathogen
includ
assay
databas
report
nonspecif
fungal
detect
categori
prefil
well
assay
strip
contain
primer
target
wide
conserv
fungal
gene
small
larg
ribosom
subunit
well
narrowli
conserv
ribosom
gene
found
fungal
mitochondria
betatubulin
gene
distribut
gene
across
fungal
divis
shown
supplement
fig
sixteenth
primer
use
control
extract
amplif
primer
pcr
cycl
condit
extract
method
shown
previou
public
massir
et
al
shin
et
al
pcr
amplif
desalt
method
purifi
amplifi
nucleic
acid
load
onto
esim
modul
mass
result
amplicon
determin
nucleotid
base
composit
amplicon
calcul
base
upon
mass
known
nucleotid
sequenc
pcr
primer
target
genom
region
base
composit
determin
uniqu
amplicon
well
assay
compar
curat
databas
databas
contain
base
composit
signatur
develop
use
data
gather
empir
simul
known
sequenc
acquir
genbank
final
identif
triangul
use
inform
gener
assay
primer
pair
sampl
process
pcresim
system
includ
three
control
introduc
variou
point
process
extract
control
ad
everi
sampl
amplifi
standalon
primer
pair
includ
assay
failur
detect
control
indic
issu
sampl
extract
downstream
failur
amplif
control
calibr
part
assay
formul
well
assay
calibr
synthet
dna
construct
design
amplifi
associ
primer
pair
easili
distinguish
organ
target
analysi
algorithm
calibr
use
reduc
low
level
background
nois
produc
pcr
control
amplif
issu
absenc
target
templat
peptid
known
mass
introduc
desalt
esim
process
provid
posit
indic
success
execut
desalt
electrospray
ioniz
step
provid
precis
calibr
point
analysi
spectra
produc
mass
spectromet
analyt
sensit
assay
verifi
low
concentr
test
multipl
strain
fungu
lod
establish
concentr
determin
count
coloni
form
unit
cfu
per
millilit
core
set
fungi
select
exercis
assay
primer
part
lod
studi
core
fungi
aspergillu
fumigatu
candida
dubliniensi
candida
glabrata
cryptococcu
neoforman
mucor
sp
initi
lod
studi
conduct
use
five
core
fungi
util
steril
salin
surrog
clinic
bal
matrix
limit
detect
determin
process
dilut
seri
five
replic
confirm
lowest
concentr
five
replic
posit
target
fungi
process
addit
replic
confirm
lod
lowest
concentr
least
replic
posit
target
fungi
limit
detect
addit
fungi
test
phylogenet
rang
assay
also
establish
use
method
describ
analyt
specif
studi
conduct
evalu
abil
assay
perform
presenc
interf
substanc
abil
assay
detect
character
multipl
target
organ
singl
sampl
crossreact
studi
conduct
multipl
speci
bacteria
virus
nontarget
fungi
high
concentr
test
assay
reproduc
evalu
test
multipl
low
concentr
replic
core
fungi
across
multipl
assay
lot
system
total
bal
sampl
prospect
collect
consent
patient
bronchoscopi
suit
john
hopkin
hospit
baltimor
md
usa
juli
decemb
inclus
patient
clinic
indic
bronchoscopi
bal
sent
microbiolog
test
exclus
patient
tachycardia
hypotens
time
bronchoscopi
histori
pulmonari
hemorrhag
syndrom
vascul
acut
coronari
syndrom
pregnanc
mechan
ventil
written
inform
consent
obtain
patient
interest
particip
particip
subject
addit
bal
wash
obtain
research
purpos
standard
care
laboratori
test
data
clinic
data
abstract
chart
review
deidentifi
prior
analysi
pcresim
studi
approv
john
hopkin
institut
board
review
irb
bal
sampl
process
john
hopkin
hospit
microbiolog
laboratori
detect
identif
fungal
pathogen
use
standard
care
refer
test
includ
direct
microscop
examin
calcofluor
white
stain
fungal
cultur
galactomannan
posit
cutoff
valu
gmi
direct
fluoresc
antibodi
dfa
microscop
examin
method
use
detect
pneumocysti
jirovecii
parallel
refer
standard
care
test
ml
direct
bal
fluid
test
pcresim
ibi
bioscienc
ca
usa
patient
chart
review
conduct
two
independ
research
data
abstract
use
standard
data
collect
instrument
includ
sex
age
underli
condit
histopatholog
find
radiolog
result
antimicrobi
regimen
clinic
outcom
laboratori
find
galactomannan
result
serum
bal
serum
betadglucan
microscopycultur
result
tissu
addit
bal
patient
proven
probabl
possibl
fungal
infect
defin
eortcmsg
european
organ
research
treatment
cancerinvas
fungal
infect
nation
institut
allergi
infecti
diseas
mycos
studi
group
criteria
de
pauw
et
al
modif
p
jirovecii
infect
probabl
pneumocysti
infect
would
appli
patient
immunocompromis
condit
clinic
featur
radiolog
evid
neg
microscop
examin
possibl
pneumocysti
infect
would
appli
patient
immunocompromis
condit
clinic
featur
radiolog
laboratori
find
limit
detect
five
core
fungal
speci
well
addit
speci
establish
supplement
fig
lod
fungal
speci
rang
cfuml
cfuml
mean
lod
cfuml
median
lod
cfuml
addit
strain
speci
lod
establish
test
near
lod
concentr
fungal
speci
includ
lod
analyt
sensit
test
exercis
phylogenet
rang
depth
assay
analyt
specif
assay
evalu
challeng
assay
high
concentr
cfuml
copiesml
nontarget
microorgan
assay
system
also
evalu
regard
suscept
interfer
endogen
exogen
substanc
expect
present
within
bal
specimen
substanc
list
supplement
tabl
test
presenc
near
lod
level
core
fungi
interfer
spuriou
detect
observ
evalu
abil
assay
correctli
detect
identifi
target
fungi
presenc
multipl
target
core
fungi
combin
one
member
core
set
near
lod
concentr
triplic
compon
mixtur
combin
detect
spuriou
detect
observ
addit
detect
rate
observ
reproduc
studi
conduct
use
replic
core
fungi
near
lod
concentr
test
use
multipl
system
assay
lot
total
patient
enrol
studi
nondupl
bal
fluid
specimen
collect
twoyear
studi
period
two
hundr
sixtytwo
sampl
includ
studi
bal
exclud
due
follow
reason
due
insuffici
sampl
volum
ml
due
invalid
test
result
pcresim
analysi
sampl
label
ninetytwo
percent
test
sampl
patient
known
immunocompromis
state
specimen
patient
transplant
patient
malign
detail
underli
diseas
spectrum
patient
list
supplementari
tabl
twentythre
sampl
obtain
immunocompet
patient
eighteen
sampl
neg
refer
standard
assay
pcresim
three
sampl
posit
yeast
candida
albican
method
none
patient
clinic
sign
fungal
infect
like
suggest
colon
one
specimen
cultur
posit
histoplasmosi
capsulatum
yield
detect
pcresim
one
specimen
detect
pcresim
coccidioid
immiti
found
cultur
neg
posit
detect
rate
refer
method
pcresim
tabl
also
assess
concord
genu
speci
level
result
posit
method
find
genu
level
concord
speci
level
concord
overal
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
posit
likelihood
ratio
lr
broad
level
fungal
detect
pcresim
respect
tabl
perform
structur
chartreview
patient
includ
clinic
present
underli
condit
imag
studi
laboratori
marker
found
specimen
patient
probabl
possibl
fungal
infect
line
factor
illustr
eortcmsg
criteria
de
pauw
et
al
seventytwo
specimen
patient
transplant
patient
malign
remain
specimen
patient
hiv
interstiti
lung
diseas
chronic
obstruct
pulmonari
diseas
et
al
fig
common
comorbid
lung
transplant
follow
hematolog
malign
fig
detail
abstract
clinic
data
patient
list
supplement
tabl
specimen
patient
clinic
context
relev
fungal
infect
sensit
specif
ppv
npv
posit
lr
pcresim
respect
tabl
aspergillu
detect
bal
sampl
cultur
andor
pcr
esim
consid
relat
lung
infect
clinic
context
includ
underli
condit
clinic
featur
lung
ct
find
fig
eighteen
detect
pcr
esim
fifteen
verifi
cultur
ten
match
culturebas
identif
speci
level
thu
sampl
posit
pcresim
refer
method
account
major
aspergillu
infectionrel
case
increas
galactomannan
valu
detect
nine
aspergillu
infectionrel
specimen
rang
posit
pcresim
culturebas
method
clinic
relev
aspergillu
detect
none
patient
cultureposit
given
antifung
agent
bal
specimen
collect
patient
posit
pcresim
neg
cultur
given
azol
specimen
taken
two
case
aspergillu
infectionrel
posit
cultur
neg
pcresim
one
case
present
posit
galactomannan
index
gmi
patient
suffer
lung
cancer
underw
chemotherapi
radiotherapi
imag
show
tini
foci
cavit
within
anterior
aspect
consolid
multifoc
patchi
foci
ground
glass
lung
particularli
middl
lower
lung
zone
case
patient
idiopath
pulmonari
fibrosi
left
lung
transplant
intermitt
voriconazol
month
without
improv
cultur
grew
aspergillu
fumigatu
posit
galactomannan
gmi
patient
mild
fever
seriou
respiratori
symptom
worsen
lung
function
sever
week
p
jirovecii
detect
pcresim
concord
refer
dfa
result
tabl
thirteen
patient
consid
probabl
pneumocysti
pneumonia
accord
clinic
present
includ
fever
cough
worsen
pulmonari
function
imag
alter
groundglass
lung
infiltr
underli
condit
patient
posit
detect
p
jirovecii
pcresim
includ
hiv
hematolog
malign
liver
transplant
patient
also
posit
dfa
hiv
case
fourteen
bal
detect
posit
malassezia
sp
pcr
esim
none
cultur
clinic
evid
possibl
fungal
infect
found
two
case
one
case
year
old
male
lung
transplant
imag
show
patchi
ground
glass
case
year
old
male
kidney
transplant
imag
show
bilater
consolid
pleural
effus
analyt
studi
updat
pcresim
platform
demonstr
system
assay
detect
divers
array
fungal
pathogen
respons
invas
fungal
infect
low
concentr
steril
salin
matrix
one
limit
lod
result
gener
steril
salin
matrix
may
done
clinic
bal
matrix
system
assay
shown
provid
reproduc
robust
result
presenc
substanc
expect
encount
bal
specimen
gener
unexpect
detect
misidentif
presenc
common
bacteri
viral
respiratori
pathogen
well
fungi
target
assay
present
specimen
contain
mixtur
low
concentr
fungi
identifi
assay
investig
clinic
perform
system
assay
evalu
bal
specimen
patient
pulmonari
fungal
infect
use
pcresim
compar
find
stand
care
refer
test
opportunist
fungal
infect
involv
ubiquit
fungi
occur
predominantli
individu
whose
immun
system
compromis
studi
subject
consid
immunedefici
due
solid
organ
transplant
bone
marrow
transplant
neutropenia
chemotherapi
andor
radiotherapi
aid
chronic
debilit
diseas
longterm
usag
corticosteroid
andor
use
immunosuppress
cytokin
antagonist
medic
practic
essenti
evalu
diagnost
accuraci
microbiolog
method
basi
clinic
relev
structur
chart
review
conduct
specimen
specimen
patient
probabl
possibl
fungal
infect
base
revis
eortcmsg
criteria
de
pauw
et
al
found
sensit
specif
ppv
npv
posit
likelihood
ratio
pcresim
significantli
increas
compar
refer
laboratori
method
alon
patient
immunocompromis
state
includ
transplant
hematolog
malign
aid
patient
vulner
popul
high
risk
invas
fungal
diseas
although
fungal
infect
found
among
patient
without
predispos
immunocompromis
factor
two
fungal
pathogen
detect
two
patient
one
strain
histoplasma
capsulatum
isol
cultur
detect
pcresim
henc
fals
neg
patient
multipl
sclerosi
anemia
imag
result
show
consolid
pattern
cm
nodul
right
upper
lobe
compat
chronic
histoplasmosi
one
strain
coccidioid
immiti
detect
pcresim
cultur
neg
bal
result
indetermin
sinc
male
patient
present
cough
chest
xray
show
filtrat
well
mediastin
adenopathi
lack
lab
result
support
coccidioidomycosi
infect
histori
travel
endem
area
avail
diagnos
unspecifi
ocular
diseas
pathogen
could
caus
agent
patient
eye
problem
vasconcelossanto
et
al
aspergillu
sp
repres
lead
caus
agent
opportunist
fungal
lung
infect
among
immunocompromis
patient
baughman
cadena
et
al
aspergillu
sp
found
frequent
colon
pathogen
airway
popul
develop
invas
pulmonari
aspergillosi
depend
level
host
immun
defici
approxim
isol
aspergillu
case
judg
relat
pulmonari
infect
case
probabl
pulmonari
aspergillosi
detect
pcresim
concord
cultur
half
case
increas
galactomannan
valu
pcresim
system
rapid
hour
comparison
culturebas
method
perform
directli
uncultur
bal
specimen
enabl
earlier
target
therapi
studi
administr
antifung
bronchoscopi
clinic
relev
specimen
cultureposit
aspergillu
voriconazol
posaconazol
amphotericin
b
use
aspergillu
detect
pcresim
indic
potenti
advantag
approach
case
prophylact
antifung
treatment
initi
prior
specimen
acquisit
although
pcr
method
potenti
high
sensit
two
probabl
aspergillosi
case
miss
pcresim
could
due
poor
qualiti
specimen
result
low
yield
aspergillu
dna
alanio
bretagn
p
jirovecii
remain
one
common
opportunist
pathogen
aid
patient
occur
patient
caus
immunodefici
thoma
jr
limper
standard
refer
method
diagnos
p
jirovecii
direct
fluoresc
microscopi
assay
specimen
obtain
bal
procop
et
al
choe
et
al
addit
p
jirovecii
detect
pcresim
neg
dfa
nt
confirm
case
anoth
molecular
assay
howev
patient
immunocompromis
patient
tabl
except
one
clinic
present
radiolog
evid
support
clinic
diagnosi
diseas
aid
patient
often
highburden
p
jirovecii
previou
studi
show
dfa
assay
posit
rate
high
choe
et
al
detect
rate
dfa
studi
nine
clinicalsuspiciouspcpinfect
hiv
patient
pcr
esim
five
nonhiv
patient
detect
pneumocysti
neg
dfa
posit
pcresim
tabl
patient
whose
immunocompromis
state
due
aid
usual
present
low
burden
p
jirovecii
difficult
diagnos
microscop
seah
et
al
fauchier
et
al
result
show
posit
p
jirovecii
detect
pcresrm
nonaid
immunocompromis
patient
find
consist
previou
studi
demonstr
realtim
pcr
assay
increas
sensit
detect
p
jirovecii
infect
hauser
et
al
therefor
pcresim
could
serv
rapid
sensit
specif
technolog
detect
p
jirovecii
especi
nonaid
immunocompromis
patient
certainli
case
need
conclus
assess
one
case
detect
pcresim
thought
free
pcp
pulmonari
infect
due
lack
correspond
clinic
present
radiolog
evid
infect
p
jirovecii
colon
hiv
nonhiv
immunocompromis
patient
freall
et
al
although
definit
evid
suggest
risk
reactiv
evolut
colon
progress
pneumonia
may
need
evalu
case
longtim
usag
specif
drug
cytokin
blocker
morri
norri
fungal
biomark
could
addit
use
test
high
neg
predict
valu
diagnosi
diseas
prognost
valu
monitor
patient
treatment
onishi
et
al
damiani
et
al
kutti
et
al
malassezia
sp
usual
colon
skin
occasion
colon
respiratori
tract
growth
malassezia
requir
specif
fungal
cultur
media
like
reason
univers
neg
cultur
result
organ
detect
pcresim
recent
malassezia
fungemia
periton
arthriti
pulmonari
infect
report
immunocompromis
patient
includ
neonat
diabet
dialysi
patient
recov
stem
cell
solid
organ
transplant
tragiannidi
et
al
velegraki
et
al
pedrosa
et
al
patient
total
parenter
nutrit
thought
risk
infect
baker
et
al
although
two
patient
yield
clinic
relev
data
support
possibl
malassezia
infect
detect
pcresim
studi
definit
diagnosi
malassezia
infect
case
need
confirm
anoth
molecular
method
patient
sever
immunocompromis
state
live
short
period
time
follow
collect
specimen
studi
pcresim
offer
way
detect
potenti
pathogen
immunocompromis
popul
overal
sensit
specif
pcresim
found
respect
posit
likelihood
ratio
patient
categor
proven
probabl
possibl
invas
fungal
infect
per
eortcmsg
guidelin
demonstr
clinic
util
technolog
especi
appli
judici
within
appropri
treatment
context
addit
clinic
set
result
would
provid
treat
clinician
within
hour
oppos
day
week
requir
result
gener
cultur
base
method
rang
fungi
detect
technolog
also
reduc
test
burden
requir
given
patient
current
molecular
technolog
gener
detect
limit
number
fungi
furthermor
autom
molecular
identif
provid
system
requir
special
train
knowledg
requir
microscop
identif
fungi
cultur
histopatholog
specimen
note
improv
eas
rapid
fungal
diagnosi
posit
effect
patient
outcom
hospit
cost
arvan
et
al
pcresim
broad
spectrum
molecular
technolog
develop
diagnosi
invas
fungal
infect
multiplex
pcr
dna
sequenc
analysi
patient
specimen
among
technolog
provid
util
similar
demonstr
pcresim
broaden
diagnost
toolkit
avail
clinician
accompani
gain
speed
accuraci
diagnosi
could
help
improv
patient
outcom
reduc
hospit
cost
help
combat
spread
antibiot
resist
unfortun
pcresim
remov
market
abbott
laboratori
primarili
due
financi
consider
ozenc
et
al
howev
present
data
well
recent
public
use
pcresim
improv
fungal
diagnosi
hematolog
patient
krifor
et
al
shed
new
light
import
develop
noncultur
base
broad
panel
molecular
assay
enhanc
detect
fungal
pathogen
patient
invas
fungal
infect
continu
develop
clinic
investig
technolog
pursu
